Sulodexide represents a novel antithrombotic agent with multiple sites of action on blood coagulation and vascular processes. The purpose of this study was to compare sulodexide and enoxaparin on anticoagulant effects, tissue factor (TF)-induced activation of platelets, inhibition of microparticle generation and to investigate their effect on heparin-induced platelet aggregation (HIPA). Sulodexide was compared with enoxaparin at equigravimetric concentrations. When compared to enoxaparin, sulodexide produced a stronger anticoagulant effect in the prothrombin time (PT), activated partial thromboplastin time (APTT), Heptest, and thrombin time (TT) assays. In addition, sulodexide had a stronger inhibitory effect on TFmediated microparticle generation (IC 50 ¼ 2.8 mg/ mL), P-selectin expression (IC 50 ¼ 4.8 mg/ml), and platelet aggregate formation (IC 50 ¼ 8.5 mg/mL) compared to higher IC 50 values with enoxaparin. Sulodexide and enoxaparin exhibited a similar effect on heparininduced thrombocytopenia (HIT) antibody-mediated platelet activation HIPA assays. These results suggest that sulodexide is a relatively stronger anticoagulant agent than enoxaparin. Sulodexide is subcutaneously absorbed. Its ability to inhibit TF-mediated platelet activation may contribute to the observed therapeutic effects of sulodexide in microvascular vasculopathy such as diabetic nephropathy. These results also suggest that inhibition of TF activation of platelets by sulodexide may be independent of its anticoagulant effects. These results warrant further investigation of sulodexide in additional preclinical and clinical studies.
Introduction
The first low-molecular-weight heparin (LMWH) was introduced for the treatment of venous thromboembolism (VTE) more than 20 years ago. 1 Enoxaparin is a LMWH, which is prepared by the depolymerization of unfractionated heparin (UFH). 2 Compared with UFH, LMWHs offer the convenience of subcutaneous administration and have greater bioavailability (90%-100%), longer half-life (t 1/2 ), a more predictable dose response, and a potentially improved safety profile. 3, 4 Lowmolecular-weight heparins have been shown to be effective and well-tolerated alternatives to UFH in treating and preventing VTE. [5] [6] [7] [8] [9] [10] Enoxaparin has a higher ratio of antifactor Xa to antifactor IIa activity than UFH (4:1). 11 This is a potential advantage in that factor Xa generation occurs earlier in the coagulation cascade, thus blocking a small amount of Xa resulting in prevention of the generation of larger amounts of thrombin. Laboratory monitoring is not generally required with LMWH therapy, except in patients with renal insufficiency. 12 Sulodexide is a well-defined mammalian glycosaminoglycan (GAG) that is composed of 2 distinct fractions. The chemical composition of sulodexide consists of 80% fast moving heparin (FMH) and 20% dermatan sulfate (DS). 13 The pharmacological effects of sulodexide differ substantially from other GAGs and are mainly characterized by a prolonged half-life (18.7 + 4.1 hour after 50 mg per os) 14 and reduced effect on global coagulation and bleeding parameters. 15 Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin and heparin cofactor II (HCII) simultaneously. 13, 14 Clinically, sulodexide is used for the prophylaxis and treatment of thromboembolic diseases; however, recent research has also demonstrated the beneficial effects of sulodexide in animal models of reperfusion injury 16 and the treatment of diabetic nephropathy. 17, 18 More recently, sulodexide is also used in the anticoagulant management of patients with heparininduced thrombocytopenia (HIT). 19 Microparticles are released from the cells following cell activation or apoptosis by triggers including chemical stimuli, such as cytokines, thrombin, and endotoxin, or physical stimuli, such as shear stress or hypoxia. Microparticles are likely to trigger coagulation by the binding of the phospholipids in microparticles to the coagulation factors, which may promote the formation and activity of coagulation enzyme complexes, a role, which has traditionally been thought to occur by activated platelets. 20 This study was designed to test the hypothesis that anticoagulant drugs may modulate TF-induced microparticle generation. To investigate this hypothesis, several studies were performed. To determine the effect of enoxaparin and sulodexide on TF activation of platelet and other cells in whole blood and its effects on microparticle generation, flow cytometry was used. In these studies, platelet activation and platelet aggregate formation were also measured.
In addition, the anticoagulant effects of enoxaparin and sulodexide in whole blood and plasma and their interaction with antibodies were determined.
Materials and Methods

Study Drugs
Enoxaparin and sulodexide were supplemented in whole blood, and pooled normal human plasma (NHP) drawn from normal healthy volunteers (n ¼ 7), in a concentration range of 0 to 25 mg/mL obtained by serial dilution. These drug preparations were immediately used. 1 . Enoxaparin (Lovenox) was obtained from sanofiaventis US (Bridgewater, NJ). 2. Sulodexide (Vessel) was obtained from Alfa Wassermann (Bologna, Italy).
Blood Preparations
1. Human whole blood was collected by venipuncture and tested immediately or mixed with 3.2% sodium citrate in a ratio of 1:10. 2. Pooled NHP collected in citric acid-sodium citrate-dextrose (ACD) was obtained from the Loyola Medical Center Blood Bank (Maywood, IL). 3. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were prepared from citrated whole blood by differential centrifugation (GS-6KR Centrifuge; Beckman Coulter, Brea, CA).
Global Clot-Based Assays 
Platelet Activation Assays
The platelet activation assay using the flow cytometer (Epics XL Flow Cytometer; Beckman Coulter, Miami, FL) was performed in a manner as previously reported. 20 Briefly stated, to whole blood drawn into sodium citrate, test drug and recombinant TF (Innovin, Dade Behring) were diluted 1:10 in 25 mmol/L CaCl 2 , added and incubated for 3 minutes at 37 C. Following fixation with 1% paraformaldehyde, samples were incubated with fluorescentlabeled monoclonal antibodies (BD Biosciences, San Jose, CA) CD61 (GPIIIa; expressed on the surface of platelets) and CD62P (P-selectin; expressed on the platelet surface after a-granule release serving as a marker for platelet activation). Using the above assay conditions, generated platelet microparticles, P-selectin expressing platelets within the entire platelet population (platelet activation) and single platelets, and platelet-platelet complexes (platelet aggregation) were quantitated.
Heparin-Induced Platelet Aggregation Assay
To test the HIT antibody-mediated aggregation profile of PRP by enoxaparin and sulodexide, sera from heparin-induced thrombocytopenia (HIT)-positive patients were used as a source of heparin-platelet factor 4 (PF4) antibodies. After blanking the aggregometer with PPP, 250 mL of PRP and 250 mL of HIT pooled test serum were added to a cuvette. After a 2-minute incubation, enoxaparin and sulodexide were added. The aggregation profile was monitored with the Platelet Aggregation profiler (PAP-4;
Bio/DATA, Horsham, PA) for 30 minutes. The aggregation studies were carried out using a final concentration of 10 mg/mL of each of these agents.
Statistical Analysis
Statistical analysis was performed using the Graph-Pad InStad program. The groups were compared using Student t test. The data were presented as mean + standard deviation, and the significance was set at P .05.
Results
Global Clot-Based Assays Figure 1A ). Similarly, in plasma, at a final concentration of 25 mg/mL, the PT values were increased to 14.4 + 0.14 seconds for sulodexide and 12.7 + 0.35 seconds for enoxaparin (P ¼ .02; Figure 1B ).
In the APTT, both enoxaparin and sulodexide showed a concentration-dependent increase in the whole blood and plasma APTT. At a final concentration of 25 mg/mL, there was a pronounced increased in the APTT value with sulodexide reaching beyond 300 seconds. With enoxaparin, the APTT values were increased to 156.7 + 5.4 seconds. A statistically significant difference was noted between the effects of enoxaparin and sulodexide at this concentration (P ¼ .001; Figure 2A ). At a final concentration of 12.5 and 6.25 mg/mL, sulodexide showed an APTT value of greater than 300 seconds and 152.5 ++ 20.5 seconds in plasma. However, enoxaparin showed an APTT value of 115.5 + 13.4 and 70.4 + 9.2 seconds (P ¼ .003 and P ¼ .035, respectively; Figure 2B ).
Specific Clot-Based Assays
In the Heptest assay, enoxaparin and sulodexide showed a concentration-dependent response in the anticoagulant effects as measured by Heptest in a final concentration of 12.5 mg/mL. The Heptest values were increased to approximately 200 seconds with both the drugs in whole blood as well as the plasma-based assay. At a final concentration of 25 mg/mL, both the drugs reached a maximum response beyond the range of measurement (300 seconds; Figure 3A and 3B).
The TT assay was found to be a more sensitive assay compared to the other assays for measurement of the effects of sulodexide. Even at a final concentration of 3.12 mg/mL, sulodexide showed an increase of 250 seconds in the WB-TT (5 U/mL with CaCl 2 ; Figure 4A ). However, the plasma TT assay only demonstrated an increase up to 25 seconds. This is an approximately 10-fold increase in the WB-TT response when compared to plasma TT at a concentration of 3.12 mg/mL. In contrast, enoxaparin did not show any increase in the WB as well as plasma TT at this concentration. Only at a final concentration of 12.5 mg/mL, enoxaparin showed an increase of 100 seconds in the WB-TT assay and was beyond the range of measurement in the plasma TT assay at the same concentration ( Figure 4B ). 
Specific Biochemical Assays
Amidolytic assays. Enoxaparin and sulodexide showed a concentration-dependent inhibition of factor IIa (FIIa). To achieve 80% inhibition of FIIa, the final concentration of sulodexide was 3.12 mg/mL; the final concentration of enoxaparin was 6.25 mg/mL ( Figure 5 ). At the final concentration of 3.12 mg/ mL, there was a statistical difference between enoxaparin and sulodexide (P ¼ .04). In addition, both enoxaparin and sulodexide showed a concentration-dependent inhibition of factor Xa (FXa). The percentage inhibition of FXa was observed to be 35.9% with enoxaparin and 23% with sulodexide at a final concentration of 3.12 mg/mL. However, a maximum inhibitory effect of approximately 90% was obtained with both these drugs at a final concentration of 25 mg/mL ( Figure 6 ).
Both these drugs produced similar anti-HCII activities. Even at a final concentration of 3.12 mg/ mL, enoxaparin and sulodexide showed similar anti-HCII activity (90%; Figure 7) . 
Flow Cytometric Studies
The inhibition of platelet microparticle generation was measured by flow cytometry. Sulodexide and enoxaparin showed a concentration-dependent inhibition of the platelet microparticle generation, following activation of platelets by TF. Although there was 1.54 + 0.31% microparticle generation with sulodexide, at a final concentration of 25 mg/mL, microparticle generation with enoxaparin at the same concentration was 4.53 + 0.81%. There was a statistically significant difference between 2 agents (P ¼ .001). Even at a final concentration of 12.5 and 6.25 mg/mL, sulodexide showed 2.01 + 0.73% and 2.74 + 0.34% generation of microparticles, whereas enoxaparin showed 4.63 + 0.75% and 4.88 + 1.13% microparticle generation at the same concentration (P ¼ .003 and P ¼ .02, respectively; Figure  8 ). Below a final concentration of 6.25 mg/mL, there was a gradual increasing trend in the microparticle formation, suggesting a relatively lower inhibitory effect of sulodexide and enoxaparin when compared to a saline control value of 10%. A lower TF concentration was used to activate platelet microparticle Figure 5 . A comparison of the effects of enoxaparin and sulodexide on the amidolytic anti-Xa assay was measured. A concentration-dependent inhibition of factor Xa could be seen. Both agents showed a similar pattern in the inhibition of factor Xa reaching a value of approximately 53%, 75%, and 87% at a final concentration of 6.25, 12.5, and 25 mg/mL, respectively. PPP indicates platelet-poor plasma. generation to evaluate differences in the microparticle inhibitory effects of enoxaparin and sulodexide. The inhibition of platelet P-selectin expression was measured by flow cytometry. Sulodexide and enoxaparin at a final concentration of 25 mg/mL caused 4.5% and 25% P-selection expression (P ¼ .04), while at a concentration of 12.5 mg/mL, they showed 11.5% and 32% P-selectin expression, respectively (P ¼ .01). Below a final concentration of 12.5 mg/mL, both the drugs exhibited a decreasing trend in the inhibition of P-selectin expression. At a final concentration of 6.25 mg/mL, sulodexide and enoxaparin showed 25.5% and 35% P-selectin expression (P ¼ .03; Figure 9 ). Thus, sulodexide was found to be more potent than enoxaparin in the inhibition of P-selectin expression.
The Effects of Enoxaparin and Sulodexide on Inhibition of Microparticle Generation by Flow Cytometry
The inhibition of platelet aggregate generation was also measured by flow cytometry. Sulodexide exhibited an almost complete inhibition of platelet aggregate generation (2.5%) at a final concentration of 25 mg/mL, while enoxaparin showed a 19% inhibition of platelet aggregate generation at the same concentration. However, there was no statistically significant difference (P >.05). Below a final concentration of 25 mg/mL, sulodexide showed a decreasing trend on the inhibition of platelet aggregate generation ( Figure 10 ).
Heparin-induced platelet aggregation assay. The HIPA responses obtained with enoxaparin and sulodexide were evaluated at the onset of platelet aggregation time, 5, 10, 15, and 30 minutes period in the presence heparin PF4 antibody. The aggregation responses were also studied using saline as a control.
The aggregation at the onset time was measured in these studies. Enoxaparin showed initiation of aggregation at 5 + 1.73 minutes, while sulodexide showed at 9 + 1.69 minutes (SEM). Enoxaparin exhibited a later effect on HIPA than sulodexide. However, there was no statistically significant difference between enoxaparin and sulodexide (P ¼ .06).
The percentage aggregation response at 5, 10, 15, and 30 minutes was also studied. No statistically significant differences were noted between the enoxaparin and the sulodexide at 5, 10, 15, and 30 minutes (P > .05; Figure 11 ).
Discussion
Sulodexide is a glycosaminoglycan mixture obtained from porcine intestinal mucosa. It contains 80% fast-moving heparin and 20% DS. It potentiates the antiprotease activities of both antithrombin III (ATIII) and HCII simultaneously, 13 thereby inhibiting thrombin generation. The inhibition of thrombin generation results in inhibition of platelet activation and generation of platelet-derived microparticles. Figure 10 . The effects of enoxaparin and sulodexide on the inhibition of platelet aggregation were measured by flow cytometry. Sulodexide shows a marked effect on the inhibition of platelet aggregation, while enoxaparin shows a relatively lower inhibition of platelet aggregation. However, these differences are not found to be statistically significant (P > .05).
The Effects of Enoxaparin and Sulodexide on Inhibition of P-selectin Expression by Flow Cytometry
There was a marginal increase in the PT values at low concentrations with sulodexide and enoxaparin that was not statistically significant. However, sulodexide at high concentrations showed a slight increase in the PT, suggesting modulation of the extrinsic pathway of coagulation. The APTT assay showed a statistically significant difference between sulodexide and enoxaparin at a final concentration of 25 mg/mL. The therapeutic concentrations of enoxaparin and sulodexide at which a 2-to 2.5-time increase in APTT response was observed were 7 and 15 mg/mL, respectively. The APTT response suggests that sulodexide is much more potent than enoxaparin in the inhibition of the intrinsic pathway of coagulation. The TT assay was found to be very sensitive in the evaluation of the anticoagulant potential of sulodexide and enoxaparin. Sulodexide was found to be much more potent than enoxaparin in the inhibition of the common pathway of coagulation. This may be due to the relatively higher molecular weight of sulodexide and stronger interaction with HCII. Based on the increase in the Heptest assay values, it is clear that both these agents equally inhibit FXa. The Heptest assay values correlated with the very similar inhibition of FXa based on the anti-Xa amidolytic assay. However, sulodexide was found to be much more potent in comparison to enoxaparin and exhibited a statistically significant difference in the anti-IIa assay at a final concentration of 3.12 mg/ mL. Thus, based on the global clotting assays sulodexide provided a more comprehensive anticoagulant profile by inhibition of the extrinsic, intrinsic, and common pathways. Similarly in the amidolytic assays, sulodexide exhibited a marked anti-IIa and also anti-Xa effect.
Circulating platelet-derived microparticles with procoagulant activity resulting in thrombosis in uremic patients has been reported earlier. 21 Furthermore, platelet-derived microparticles play an important role in acute arterial occlusion in atherosclerotic arteries. 22, 23 Other thrombotic disorders such as cerebrovascular accidents, unstable angina, and acute myocardial infarction manifest elevated levels of platelet microparticles. [24] [25] [26] These microparticles are known to carry membrane receptors for coagulation factor Va and provide a catalytic surface for the prothrombinase reaction, resulting in thrombin generation. 27, 28 Recombinant TF produced activation of the platelets in citrated whole blood as measured by microparticle generation, platelet aggregate formation, and P-selectin expression as studied by flow cytometric method. It showed a concentrationdependent effect on inhibition of microparticle generation as studied by flow cytometry. The generation of these microparticles plays an important role in the microvascular pathogenesis observed in diabetic nephropathy. At a concentration of 1.56 mg/mL sulodexide, there was an almost complete inhibition of the microparticle generation. A sustained reduction was noticed with concentrations higher than 12.5 mg/mL up to 25 mg/mL. Although enoxaparin showed a similar reduction in microparticle generation, a comparison of the effects of these agents showed a statistically significant difference in microparticle generation. Tissue factor produced a marked activation of platelets in terms of P-selectin expression (85%). Both the enoxaparin and the sulodexide produced a strong inhibition of P-selectin expression in a concentration-dependent fashion. The IC 50 for sulodexide to inhibit P-selectin expression was much lower (4.8 mg/mL) than when compared to enoxaparin (6.25 mg/mL) in the inhibition of P-selectin expression.
Heparin-induced platelet aggregation testing was positive in the presence of sulodexide and enoxaparin. Both these agents exhibited a similar aggregation profile in the HIPA assay. At a final concentration of 10 mg/mL, the percentage aggregation profiles at 30 minutes were 66.7% for enoxaparin and 67% with sulodexide. Because both these agents are heparinoids, derived from heparin, this effect on HIPA is quite likely. There are some reports of the use of sulodexide in the management of HIT. 29 However, caution is necessary when either sulodexide or enoxaparin is given in the management of HIT for possible cross-reactivity with heparin PF4 antibodies.
One of the advantages of sulodexide is that it can be either administered orally or intravenously. Enoxaparin is available for administration either subcutaneously or intravenously and not available in oral formulation. Oral administration of sulodexide provides an advantage over enoxaparin in ease of administration and possibly decreased chances of bleeding complications.
Sulodexide has been recently shown to produce therapeutic effects in diabetic nephropathy. 30, 31 A Phase III clinical trial on the use of sulodexide in patients with early diabetic nephropathy manifested by microalbuminuria (Keryx Biopharmaceuticals New York, USA) has just been completed. Although this study did not reach its target, it did demonstrate the therapeutic efficacy of sulodexide in this specific indication. Another study showed that sulodexide also improved endothelial dysfunction, 32 and showed anti-inflammatory effects. 33 In summary, sulodexide and enoxaparin produced varying effects in the whole blood and plasma-based systems. In the whole blood studies, sulodexide produced a relatively stronger anticoagulant effect than enoxaparin. In the antiprotease assays carried out in the citrated plasma, enoxaparin produced a relatively stronger anti-Xa but weaker anti-IIa activities. In the global anticoagulant tests such as the PT and APTT, sulodexide produced a stronger anticoagulant effect than enoxaparin. In the TT assay, sulodexide produced a stronger anticoagulant effect. These results suggest that despite lower antiprotease activities in plasma-based systems, sulodexide produced a stronger anticoagulant effect in whole blood and plasma-based systems.
Recombinant TF produced activation of the platelets in citrated whole blood as measured by microparticle generation, platelet aggregate formation, and P-selectin expression as studied by flow cytometric method. Low-molecular-weight heparin enoxaparin and heparinoids such as sulodexide produced varying differential inhibitory effects on the TF-mediated activation of platelets in citrated whole blood. Sulodexide produced inhibition of TFmediated microparticle formation (IC 50 ¼ 2.8 vs 6.25 mg/mL), P-selectin expression (IC 50 ¼ 4.8 mg/ mL vs 6.25 mg/mL), and platelet aggregate formation (IC 50 ¼ 8.5 mg/mL vs not reached) more potently than enoxaparin.
These results suggest that heparin and heparinoids mediated their differential modulatory effects on platelet activation. Sulodexide produced inhibitory effects on microparticle generation, P-selectin expression, and platelet aggregate formation. These important effects of sulodexide may be quite beneficial in the management of patients with end-stage renal disease. Because sulodexide can be used orally, it offers an added advantage in the management of arterial thrombosis and associated disorders. Enoxaparin is not bioavailable after oral administration, whereas sulodexide is bioavailable after oral administration.
The studies reported in this manuscript were carried out in the in vitro systems using various assays to understand the mechanisms of the therapeutic action of this orally bioavailable glycosaminoglycan mixture. However, similar studies are warranted in animal models and human studies after oral administration of this drug simulating the therapeutic use of sulodexide. Moreover, being a polyelectrolyte, sulodexide may be capable of releasing endogenous mediators such as TFPI that can only be demonstrated in the in vivo studies.
Conclusion
The results reported in this manuscript suggest that sulodexide exhibits significant anticoagulant and antiprotease effects and is capable of inhibiting TFmediated platelet activation. This effect may contribute to the observed therapeutic effects of sulodexide in diabetic nephropathy and related disorders. These results also suggest that inhibition of TF activation of platelets by sulodexide may be independent of its anticoagulant effects. Thus, sulodexide may have multiple sites of action.
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